株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国の造影剤・放射性医薬品市場

Contrast Agents and Radiopharmaceuticals | Market Analysis | US | 2016

発行 Decision Resources Group - Medtech Solutions 商品コード 140085
出版日 ページ情報 英文 67 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
米国の造影剤・放射性医薬品市場 Contrast Agents and Radiopharmaceuticals | Market Analysis | US | 2016
出版日: 2016年09月30日 ページ情報: 英文 67 Pages
概要

米国の造影剤・放射性医薬品市場はCEUS(造影超音波) およびPET検査診断において造影剤の使用が拡大することによって成長が促進される見通しです。しかしながら同市場は、モダリティによってはガドリニウムおよび放射線の暴露といった健康への影響が起こるという不安定要素で幾分成長が限定されるでしょう。また、バリューベースケア(患者の選好・価値観に基づく医療)への移行が、最も精密で鮮明な画像を提供する診断方法の活用を支持している一方で、その利用を妨げることにもなります。

当レポートでは、米国における造影剤および放射性医薬品市場全体、およびセグメント別市場の概要と分析、競合の分析などを提供しています。

エグゼクティブサマリー

履歴

第1章 造影剤および放射性医薬品市場

  • 市場概要
  • 市場定義
  • 市場予測データ
  • 市場動向
  • 競合概要
  • 競合情勢
  • 市場シェア
  • 市場要素と発展

第2章 放射性医薬品市場

  • 市場概要
  • 市場定義
  • 市場予測データ
  • 市場動向
  • 競合概要
  • 市場シェア

第3章 CTおよびX線造影剤市場

  • 市場概要
  • 市場定義
  • 市場予測データ
  • 市場動向
  • 競合概要
  • 市場シェア

第4章 MRI造影剤市場

  • 市場概要
  • 市場定義
  • 市場予測データ
  • 市場動向
  • 競合概要
  • 市場シェア

第5章 超音波造影剤市場

  • 市場概要
  • 市場定義
  • 市場予測データ
  • 市場動向
  • 競合概要
  • 市場シェア

付録:分析手法

付録:略語・頭語集

付録:参考文献

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: M360RP0007

Growth in the US market for contrast agents and radiopharmaceuticals will be driven by the expanded use of imaging agents in CEUS and PET procedures. However, the market will be somewhat limited by uncertainty surrounding the health impacts of gadolinium and radiation exposure in certain modalities, while the shift to value-based care will hinder the use of some procedures while supporting the use of those that provide the most accuracy and clarity of visualization.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals in the US across a 10-year period.

Questions Answered in This Report:

The FDA recently expanded approval for the use of CEUS in radiology procedures.

  • What procedures does this approval extend to? What additional procedures could be approved in the future?
  • Which contrast agents received FDA approval?
  • How will competitors that do not have FDA approval react?

Looming concerns over the effects of gadolinium retention will negatively affect the use of contrast-enhanced MRI.

  • How are ACOs, health networks, and physicians responding to the recent findings on gadolinium retention?
  • What are the key differences between linear and macrocylic GBCAs and how will market demand for these products shift over the forecast period?
  • Will other imaging modalities cannibalize contrast-enhanced MRI procedures?

While less concerning than in the past, radiation dose concerns still exert a limiting effect on procedure volumes for some imaging modalities.

  • How are US radiologists responding and what methods are they using to ensure image quality?
  • Which procedures are being cannibalized by other modalities that do not require radiation for image acquisition?

The SPECT radiopharmaceuticals industry is taking precautionary measures to insulate itself from the effects of the Chalk River nuclear reactor decommission.

  • What are nuclear pharmacies doing to ensure a steady supply of technetium? How are GPOs and hospitals responding?
  • What other major legislative factors will further complicate the supply of technetium over the forecast period?
  • How is this impacting the transition away from HEU to LEU nuclear reactors?
  • How will this impact ASPs in the US market?

Table of Contents

Table of Contents

Tables and Figures

Executive Summary

Version History

1 Contrast Agent and Radiopharmaceutical Market

  • 1.1 Market Highlights
  • 1.2 Market Definitions
  • 1.3 Market Forecast Data
  • 1.4 General Market Trends
  • 1.5 Competitive Highlights
  • 1.6 Competitive Landscape
  • 1.7 Market Shares
  • 1.8 Market Factors and Developments

2 Radiopharmaceutical Market

  • 2.1 Market Highlights
  • 2.2 Market Definitions
  • 2.3 Market Forecast Data
  • 2.4 General Market Trends
  • 2.5 Competitive Highlights
  • 2.6 Market Shares

3 CT and X-Ray Contrast Agent Market

  • 3.1 Market Highlights
  • 3.2 Market Definitions
  • 3.3 Market Forecast Data
  • 3.4 General Market Trends
  • 3.5 Competitive Highlights
  • 3.6 Market Shares

4 MRI Contrast Agent Market

  • 4.1 Market Highlights
  • 4.2 Market Definitions
  • 4.3 Market Forecast Data
  • 4.4 General Market Trends
  • 4.5 Competitive Highlights
  • 4.6 Market Shares

5 Ultrasound Contrast Agent Market

  • 5.1 Market Highlights
  • 5.2 Market Definitions
  • 5.3 Market Forecast Data
  • 5.4 General Market Trends
  • 5.5 Competitive Highlights
  • 5.6 Market Shares

Appendix: Methodology

Appendix: Acronyms and Initialisms

Appendix: Bibliography

Tables and Figures

  • Figure 1: Contrast Agent and Radiopharmaceutical Market, by Product Type, US (USD), 2014-2024
  • Table 1: Contrast Agent and Radiopharmaceutical Market Landscape, US (USD), 2015 and 2024
  • Table 2: Contrast Agent and Radiopharmaceutical Market Leaders, by Product Type and Revenue, US, 2015
  • Table 3: Companies Mentioned
  • Table 4: Factors Impacting the Contrast Agent and Radiopharmaceutical Market, by Product Type, US
  • Table 5: Recent Events in the Contrast Agent and Radiopharmaceutical Market, US
  • Table 6: Emerging Products for the Contrast Agent and Radiopharmaceutical Market, US
  • Table 7: Key Report Updates
  • Table 8: Contrast Agent and Radiopharmaceutical Procedures and Products Covered, US
  • Table 9: Version History
  • Figure 2: Contrast Agent and Radiopharmaceutical Market, by Product Type, US (USD), 2014-2024
  • Table 10: Contrast Agent and Radiopharmaceutical Market, by Product Type, US (USD), 2014-2024
  • Table 11: Contrast Agent and Radiopharmaceutical Market Growth, by Product Type, US, 2015-2024
  • Figure 3: Contrast Agent and Radiopharmaceutical Revenue Market Shares, US, 2015
  • Table 12: Contrast Agent and Radiopharmaceutical Revenue Market Shares, by Product Type, US, 2015
  • Table 13: Factors Impacting the Contrast Agent and Radiopharmaceutical Market, by Product Type, US
  • Table 14: Recent Events in the Contrast Agent and Radiopharmaceutical Market, US
  • Table 15: Emerging Products for the Contrast Agent and Radiopharmaceutical Market, US
  • Figure 4: Radiopharmaceutical Market, by Product Type, US (USD), 2014-2024
  • Table 16: Radiopharmaceutical Market, by Product Type, US (USD), 2014-2024
  • Table 17: Radiopharmaceutical Market Growth, by Product Type, US, 2015-2024
  • Table 18: Nuclear Medicine System Installed Base, by Product Type, US, 2014-2024
  • Figure 5: Radiopharmaceutical Revenue Market Shares, US, 2015
  • Table 19: Radiopharmaceutical Revenue Market Shares, by Product Type, US, 2015
  • Figure 6: CT and X-Ray Contrast Agent Market, by Product Type, US (USD), 2014-2024
  • Table 20: CT and X-Ray Contrast Agent Market, by Product Type, US (USD), 2014-2024
  • Table 21: CT and X-Ray Contrast Agent Market Growth, by Product Type, US, 2015-2024
  • Table 22: CT Device Market, by Procedure Type, US (USD), 2014-2024
  • Table 23: CT Device Market Growth, by Procedure Type, US , 2015-2024
  • Table 24: CT and X-Ray System Installed Base, by Product Type, US, 2014-2024
  • Figure 7: CT and X-Ray Contrast Agent Revenue Market Shares, US, 2015
  • Table 25: CT and X-Ray Contrast Agent Revenue Market Shares, US, 2015
  • Figure 8: MRI Contrast Agent Market, by Procedure Type, US (USD), 2014-2024
  • Table 26: MRI Contrast Agent Market, by Procedure Type, US (USD), 2014-2024
  • Table 27: MRI Contrast Agent Market Growth, by Procedure Type, US, 2015-2024
  • Table 28: MRI System Installed Base, by Procedure Type, US, 2014-2024
  • Figure 9: MRI Contrast Agent Revenue Market Shares, US, 2015
  • Table 29: MRI Contrast Agent Revenue Market Shares, US, 2015
  • Figure 10: Ultrasound Contrast Agent Market, US (USD), 2014-2024
  • Table 30: Ultrasound Contrast Agent Market, US (USD), 2014-2024
  • Figure 11: Ultrasound Contrast Agent Revenue Market Shares, US, 2015
  • Table 31: Ultrasound Contrast Agent Revenue Market Shares, US, 2015
  • Table 32: Acronyms and Initialisms
Back to Top